Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Farmers Insurance
Johnson and Johnson
Accenture
QuintilesIMS
McKesson
US Army
Boehringer Ingelheim
Argus Health
Federal Trade Commission

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203389

« Back to Dashboard

NDA 203389 describes PROCYSBI, which is a drug marketed by Horizon Pharma Usa and is included in one NDA. It is available from two suppliers. There are five patents protecting this drug. Additional details are available on the PROCYSBI profile page.

The generic ingredient in PROCYSBI is cysteamine bitartrate. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the cysteamine bitartrate profile page.
Summary for 203389
Tradename:PROCYSBI
Applicant:Horizon Pharma Usa
Ingredient:cysteamine bitartrate
Patents:5
Therapeutic Class:Enzyme Replacements/Modifiers
Formulation / Manufacturing:see details
Pharmacology for NDA: 203389
Mechanism of ActionCystine Disulfide Reduction
Suppliers and Packaging for NDA: 203389
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389 NDA Raptor Therapeutics Inc. 49663-001 49663-001-06 60 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE, PLASTIC (49663-001-06)
PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389 NDA Raptor Therapeutics Inc. 49663-002 49663-002-25 250 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE, PLASTIC (49663-002-25)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED RELEASE;ORALStrengthEQ 25MG BASE
Approval Date:Apr 30, 2013TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 14, 2018
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Regulatory Exclusivity Expiration:Apr 30, 2020
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY
Regulatory Exclusivity Expiration:Aug 14, 2022
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Cerilliant
Cipla
McKesson
Fuji
Medtronic
Cantor Fitzgerald
Argus Health
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot